Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5614
Abstract: [177Lu]Lu-PSMA-617 (LuPSMA) radionuclide therapy improves overall survival in mCRPC, and was recently approved by the FDA. Nevertheless, owing to the heterogeneous nature of mCRPC, responses to LuPSMA therapy can be variable, and resistance is inevitable.… read more here.
Keywords: ctdna; psa pfs; variant; mcrpc ... See more keywords
Examining laboratory-based VISION eligibility and 177Lu-PSMA-617 outcomes in patients with metastatic castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e17062
Abstract: e17062 Background: Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA-617) is an FDA-approved therapy for metastatic castration-resistant prostate cancer (mCRPC) and commonly used in late-line treatment for patients with extensive disease and diminished organ function. It is unclear… read more here.
Keywords: psma 617; vision; vision vision; 177lu psma ... See more keywords